{"id":533,"date":"2026-04-23T14:05:46","date_gmt":"2026-04-23T18:05:46","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=533"},"modified":"2026-04-23T16:26:15","modified_gmt":"2026-04-23T20:26:15","slug":"dea-issues-order-expediting-cannabis-rescheduling-to-schedule-iii","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2026\/04\/23\/dea-issues-order-expediting-cannabis-rescheduling-to-schedule-iii\/","title":{"rendered":"DEA Issues Order Expediting Cannabis Rescheduling to Schedule III"},"content":{"rendered":"\n<p>By <a href=\"https:\/\/www.duanemorris.com\/attorneys\/paulpjosephson.html\">Paul P. Josephson<\/a>, <a href=\"https:\/\/www.duanemorris.com\/attorneys\/michaeldschwamm.html\">Michael D. Schwamm<\/a> and <a href=\"https:\/\/www.duanemorris.com\/attorneys\/tracyagallegos.html\">Tracy Gallegos<\/a><\/p>\n\n\n\n<p>On April 22, 2026, a final order issued by the Acting Attorney General and the Drug Enforcement Administration took effect, fundamentally altering the federal regulatory landscape for marijuana. The order moves FDA-approved drug products containing marijuana and marijuana subject to qualifying state-issued medical marijuana licenses from Schedule I to Schedule III of the Controlled Substances Act (CSA).<\/p>\n\n\n\n<p>Though a welcome and long hoped-for action, it is critical to note this is <em>not <\/em>a broad legalization of all adult use (recreational) cannabis sales. Nor does it legalize the controversial category of hemp-derived THC products.<\/p>\n\n\n\n<p>Read more about the order on the <a href=\"https:\/\/blogs.duanemorris.com\/cannabis\/2026\/04\/23\/relief-finally-dea-issues-order-expediting-cannabis-rescheduling-to-schedule-iii\/\">Duane Morris Cannabis Industry Blog<\/a>. <br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By Paul P. Josephson, Michael D. Schwamm and Tracy Gallegos On April 22, 2026, a final order issued by the Acting Attorney General and the Drug Enforcement Administration took effect, fundamentally altering the federal regulatory landscape for marijuana. The order moves FDA-approved drug products containing marijuana and marijuana subject to qualifying state-issued medical marijuana licenses &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2026\/04\/23\/dea-issues-order-expediting-cannabis-rescheduling-to-schedule-iii\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DEA Issues Order Expediting Cannabis Rescheduling to Schedule III&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[221,728,729],"ppma_author":[521],"class_list":["post-533","post","type-post","status-publish","format-standard","hentry","category-general","tag-life-sciences","tag-marijuana","tag-schedule-iii"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=533"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/533\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=533"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}